KYMR — Kymera Therapeutics Share News
0.000.00%
Last trade - 00:00- $8.99bn
- $8.30bn
- $39.21m
Kymera Therapeutics up after $250 mln stock sale
Brief: Kymera Therapeutics Announces Pricing Of $250 Million Public Offering
U.S. RESEARCH ROUNDUP- Aerovironment, Cisco, Dell Technologies
Kymera Therapeutics falls after launching $250 mln stock offering
Brief: Kymera Therapeutics Commences $250 Million Public Offering
Gilead signs up to $750 million cancer drug deal with Kymera Therapeutics
Brief: Kymera Therapeutics Announces Sanofi Irak4 Collaboration Update
Brief: Gilead Sciences And Kymera Therapeutics Enter Into Exclusive Option And License Agreement
U.S. STOCKS ON THE MOVE-Guardant Health, Hewlett Packard Enterprise, Venture Global
U.S. STOCKS ON THE MOVE-Intel, Guardant Health, CrowdStrike
U.S. STOCKS ON THE MOVE-Hims & Hers Health, Microstrategy, FedEx
Brokerages turn bullish on Kymera after positive early trial data
U.S. RESEARCH ROUNDUP-Biomea Fusion, GE Aerospace, P&G
U.S. STOCKS ON THE MOVE-Natgas companies, UnitedHealth, Cactus
U.S. STOCKS ON THE MOVE-Lyra Therapeutics, Church & Dwight, Applied Digital
U.S. STOCKS ON THE MOVE-Xilio Therapeutics, Red Rock Resorts, Kymera
Kymera rises after positive early-stage results for experimental drug
Brief: Kymera Therapeutics Announces Positive First-In-Human Results From Phase 1 Healthy Volunteer Clinical Trial Of KT-621
Kymera Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary